Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 13/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 10/20 | 0.42 |
| ▸ | C5AR1 | P21730 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9978031 | 0.91 | CYP3A4 (0.57) | CYP3A4OPRL1OPRM1CYP2D6 | |
| SCHEMBL9978060 | 0.90 | CYP3A4 (0.42) | CYP3A4OPRL1OPRM1 | |
| SCHEMBL9978104 | 0.87 | OPRL1 (0.45) | CYP3A4OPRL1OPRM1C5AR1CYP2D6 | |
| SCHEMBL16696092 | 0.84 | OPRL1 (0.48) | CYP3A4OPRL1OPRM1C5AR1CYP2D6 | |
| SCHEMBL9978093 | 0.83 | CYP3A4 (0.49) | CYP3A4OPRL1OPRM1CYP2D6TSHR | |
| SCHEMBL9977962 | 0.83 | CYP3A4 (0.64) | CYP3A4OPRL1OPRM1CYP2D6TSHR | |
| SCHEMBL16696133 | 0.82 | CYP3A4 (0.41) | CYP3A4OPRL1TSHRMAPK1 | |
| SCHEMBL18053773 | 0.81 | OPRL1 (0.45) | CYP3A4OPRL1OPRM1C5AR1CYP2D6 | |
| SCHEMBL16696121 | 0.81 | C5AR1 (0.49) | CYP3A4OPRL1OPRM1C5AR1 | |
| SCHEMBL18053771 | 0.81 | OPRL1 (0.46) | CYP3A4OPRL1OPRM1C5AR1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9890178-B2 | Azabenzimidazoles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2018-02-13 | — | — | US | disclosed |
| US-9890178-B2 | Azabenzimidazoles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2018-02-13 | — | — | US | disclosed |
| US-9890178-B2 | Azabenzimidazoles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2018-02-13 | — | — | US | disclosed |
| US-20160237096-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-18 | — | — | US | disclosed |
| US-20160237096-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-18 | — | — | US | disclosed |
| US-20160237096-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-18 | — | — | US | disclosed |
| US-9321767-B2 | Azabenzimidazoles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2016-04-26 | — | — | US | disclosed |
| US-9321767-B2 | Azabenzimidazoles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2016-04-26 | — | — | US | disclosed |
| US-9321767-B2 | Azabenzimidazoles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2016-04-26 | — | — | US | disclosed |
| EP-2651933-B1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-03-16 | — | — | EP | disclosed |
| US-20160045528-A1 | COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS | ALIOS BIOPHARMA, INC. | 2016-02-18 | — | — | US | disclosed |
| US-20150073012-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2015-03-12 | — | — | US | disclosed |
| US-20150073012-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2015-03-12 | — | — | US | disclosed |
| US-20150073012-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2015-03-12 | — | — | US | disclosed |
| US-8927720-B2 | Azabenzimidazoles as respiratory syncytial virus antiviral agents | JANSSEN R&D IRELAND (IE) | 2015-01-06 | — | — | US | disclosed |
| US-8927720-B2 | Azabenzimidazoles as respiratory syncytial virus antiviral agents | JANSSEN R&D IRELAND (IE) | 2015-01-06 | — | — | US | disclosed |
| US-8927720-B2 | Azabenzimidazoles as respiratory syncytial virus antiviral agents | JANSSEN R&D IRELAND (IE) | 2015-01-06 | — | — | US | disclosed |
| US-20130261151-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN R & D IRELAND (IE) | 2013-10-03 | — | — | US | disclosed |
| US-20130261151-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN R & D IRELAND (IE) | 2013-10-03 | — | — | US | disclosed |
| WO-2012080449-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN R&D IRELAND (IE) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237096-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | AZI2, ZC3HAV1, ZC3HAV1L | CYP3A4 167/4885OPRL1 4828/4885OPRM1 2873/4885 |
| US-20150073012-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | ZC3HAV1, AZI2, ZC3HAV1L | CYP3A4 149/4885OPRL1 4833/4885OPRM1 2757/4885 |
| US-20160045528-A1 | COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS | MAVS, EIF2AK2, SARS1 | CYP3A4 4543/4885OPRL1 3562/4885OPRM1 3451/4885 |
| US-20130261151-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | ZC3HAV1, AZI2, ZC3HAV1L | CYP3A4 149/4885OPRL1 4833/4885OPRM1 2757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.